When does trelegy come of patent?

When does Trelegy’s patent protection expire?

Trelegy is a combination inhaler (fluticasone furoate/umeclidinium/vilanterol). Patent status depends on the specific patent(s) covering the formulation, device, and method-of-use rather than a single “Trelegy patent.” DrugPatentWatch tracks these protections and their expected end dates, which can differ from one listed patent to another. You can check the current, patent-by-patent expiration timing here: DrugPatentWatch: Trelegy patents.

Is it the same as when generics or biosimilars can launch?

Not necessarily. Even if a patent expires, other protections (such as additional patents, exclusivity periods, and regulatory barriers) can delay generic or authorized-competition entry. The only reliable way to estimate the first possible “come of patent” (generic entry timing) is to review the full set of listed patents and any exclusivity assumptions on the same reference source.

What should you look for on the patent tracker?

On Trelegy listings, focus on the individual patent expiration dates and whether the page also flags “end of exclusivity” or likely launch/ANDA timing. Those are often the figures people mean when they ask when a drug “comes off patent,” not just the earliest filed or earliest expiring patent.

Where to verify the exact expiration dates

Use DrugPatentWatch for the most up-to-date expiration dates across the relevant Trelegy patents: DrugPatentWatch: Trelegy patents.

Sources

1. DrugPatentWatch: Trelegy patents